BrightAccountsProduction v1.0.0 v1.0.0 2024-01-01 The company was not dormant during the period The company was trading for the entire period The principal activity of the company is to provide services to clients in the area of medicinal product importation and batch release. 30 September 2025 0 0 14844184 2024-12-31 14844184 2023-12-31 14844184 2022-12-31 14844184 2024-01-01 2024-12-31 14844184 2023-01-01 2023-12-31 14844184 uk-bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 14844184 uk-curr:PoundSterling 2024-01-01 2024-12-31 14844184 uk-bus:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 14844184 uk-bus:FullAccounts 2024-01-01 2024-12-31 14844184 uk-core:ShareCapital 2024-12-31 14844184 uk-core:ShareCapital 2023-12-31 14844184 uk-core:RetainedEarningsAccumulatedLosses 2024-12-31 14844184 uk-core:RetainedEarningsAccumulatedLosses 2023-12-31 14844184 uk-core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests 2024-12-31 14844184 uk-core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests 2023-12-31 14844184 uk-bus:FRS102 2024-01-01 2024-12-31 14844184 uk-bus:Audited 2024-01-01 2024-12-31 14844184 uk-core:CurrentFinancialInstruments 2024-12-31 14844184 uk-core:CurrentFinancialInstruments 2023-12-31 14844184 uk-core:WithinOneYear 2024-12-31 14844184 uk-core:WithinOneYear 2023-12-31 14844184 uk-core:ParentEntities 2024-01-01 2024-12-31 14844184 uk-core:UltimateParent 2024-01-01 2024-12-31 14844184 2024-01-01 2024-12-31 14844184 uk-bus:Director2 2024-01-01 2024-12-31 14844184 uk-bus:Director3 2024-01-01 2024-12-31 xbrli:pure iso4217:GBP xbrli:shares
 
 
 
MIAS Pharma UK Limited
 
Financial Statements
 
for the financial year ended 31 December 2024
MIAS Pharma UK Limited
Company Registration Number: 14844184
BALANCE SHEET
as at 31 December 2024

2024 2023
Notes £ £
 
Current Assets
Debtors 7 283,564 91,900
Cash at bank and in hand 22,815 12,876
───────── ─────────
306,379 104,776
───────── ─────────
Creditors: amounts falling due within one year 8 (564,892) (260,294)
───────── ─────────
Net Current Liabilities (258,513) (155,518)
───────── ─────────
Total Assets less Current Liabilities (258,513) (155,518)
═════════ ═════════
 
Capital and Reserves
Called up share capital 100 100
Retained earnings (258,613) (155,618)
───────── ─────────
Equity attributable to owners of the company (258,513) (155,518)
═════════ ═════════
 
The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A (Small Entities).
           
The company has taken advantage of the exemption under section 444 not to file the Profit and Loss Account and Directors' Report.
           
Approved by the Board and authorised for issue on 27 September 2025 and signed on its behalf by
           
           
Pierre Baviera     Milan Portengen
Director     Director
           



MIAS Pharma UK Limited
NOTES TO THE FINANCIAL STATEMENTS
for the financial year ended 31 December 2024

   
1. General Information
 
MIAS Pharma UK Limited is a private company limited by shares incorporated and registered in the United Kingdom. The registered number of the company is 14844184. The registered office of the company is Vision Park, Chivers Way, Histon, Cambridge, Cambridgeshire, CB249AD, United Kingdom which is also the principal place of business of the company. The principal activity of the company is to provide services to clients in the area of medicinal product importation and batch release. The financial statements have been presented in Pound (£) which is also the functional currency of the company.
         
2. Summary of Significant Accounting Policies
 
The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.
 
Statement of compliance
The financial statements of the company for the financial year ended 31 December 2024 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2006.
 
Basis of preparation
The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets.
 
Turnover
Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.
 
Trade and other debtors
Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.
 
Trade and other creditors
Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.
 
Employee benefits
The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund.
 
Taxation and deferred taxation
Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements. Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.
 
Foreign currencies
Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.
 
Ordinary share capital
The ordinary share capital of the company is presented as equity.
   
3. Period of financial statements
 
The comparative figures relate to the 8 month period ended 31 December 2023.
   
4. Going concern
 
The Company incurred a loss in the current period of £102,995 and at 31st December 2024 has net current liabilities of £258,513. At 31st December 2024 the Parent Company is owed £504,515. The Company has received assurances from its Parent Company that it will not seek repayment of this loan until the Company has the ability to do so. In addition, financial and cashflow projections indicate that the company will be profitable in the near future.

For the reasons set out above the directors consider it appropriate to prepare the financial statements on a going concern basis.
   
5. INFORMATION RELATING TO THE AUDITOR'S REPORT
 
The Audit Report was unqualified. There were no matters to which the auditor was required to refer by way of emphasis.
 
The financial statements were audited by BFCD.
The Auditor's Report was signed by Dara Ó Gaora (Senior Statutory Auditor) for and on behalf of BFCD on 30th September 2025.
 
       
6. Employees
 
The average monthly number of employees, including directors, during the financial year was 3, (2023 - 2).
       
7. Debtors 2024 2023
  £ £
 
Trade debtors 277,966 86,521
Taxation  (Note 9) 114 2,888
Prepayments and accrued income 5,484 2,491
  ───────── ─────────
  283,564 91,900
  ═════════ ═════════
       
8. Creditors 2024 2023
Amounts falling due within one year £ £
 
Trade creditors 11,779 64,241
Amounts owed to group undertakings 504,515 159,383
Taxation  (Note 9) 17,187 7,930
Accruals 31,411 28,740
  ───────── ─────────
  564,892 260,294
  ═════════ ═════════
       
9. Taxation 2024 2023
  £ £
 
Debtors:
VAT 114 2,888
  ═════════ ═════════
Creditors:
PAYE / NI 17,187 7,930
  ═════════ ═════════
       
10. Capital commitments
 
The company had no material capital commitments at the financial year-ended 31 December 2024 (2023: £Nil).
           
11. Related party transactions
 
The company has availed of the exemption under FRS 102 Section 1A in relation to the disclosure of the transactions with group undertakings.
   
12. Parent and ultimate parent company
 
The company regards MIAS Pharma Limited as its parent company.
 
On 30 July 2024, MIAS Pharma Group Holdings Limited was acquired by Normec Holding Ireland Limited. From this date, the ultimate parent company is considered Newton Dutch Bidco B.V., a company incorporated in Netherlands.

The parent of the largest group in which results are consolidated is considered Newton Dutch Bidco B.V.
   
13. Controlling interest
 
The company is under the control of Newton Dutch Bidco B.V.
   
14. Post-Balance Sheet Events
 
There have been no significant events affecting the company since the financial year-end.